RNA

Company Overview — What Does Avidity Biosciences, Inc. Do?

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Avidity Biosciences, Inc. (RNA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sarah Boyce and employs approximately 190 people. With a market capitalization of $209M, RNA is one of the notable companies in the Healthcare sector.

Avidity Biosciences, Inc. (RNA) Stock Rating — Avoid (April 2026)

As of April 2026, Avidity Biosciences, Inc. receives a Avoid rating with a composite score of 28.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.RNA ranks #4,345 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Avidity Biosciences, Inc. ranks #797 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RNA Stock Price and 52-Week Range

Avidity Biosciences, Inc. (RNA) currently trades at $12.71. The stock lost $1.01 (7.4%) in the most recent trading session. The 52-week high for RNA is $73.06, which means the stock is currently trading -82.6% from its annual peak. The 52-week low is $12.29, putting the stock 3.4% above its annual trough. Recent trading volume was 1.0M shares, reflecting moderate market activity.

Is RNA Overvalued or Undervalued? — Valuation Analysis

Avidity Biosciences, Inc. (RNA) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.13x, versus the sector average of 2.75x. The price-to-sales ratio is 10.73x, compared to 1.66x for the average Healthcare stock.

At current multiples, Avidity Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Avidity Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

Avidity Biosciences, Inc. (RNA) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -31.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -27.0% versus the sector average of -33.1%.

On a margin basis, Avidity Biosciences, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -4631.0% (sector: -66.1%). Net profit margin stands at -4072.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 510.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RNA Debt, Balance Sheet, and Financial Health

Avidity Biosciences, Inc. has a debt-to-equity ratio of 16.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.20x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $350M.

RNA has a beta of 1.25, meaning it is more volatile than the broader market — a $10,000 investment in RNA would be expected to move 24.9% more than the S&P 500 on any given day. The stability factor score for Avidity Biosciences, Inc. is 22/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Avidity Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Avidity Biosciences, Inc. reported revenue of $20M and earnings per share (EPS) of $-4.97. Net income for the quarter was $-528M. Gross margin was 100.0%. Operating income came in at $-590M.

In FY 2025, Avidity Biosciences, Inc. reported revenue of $19M and earnings per share (EPS) of $-4.97. Net income for the quarter was $-685M. Revenue grew 72.1% year-over-year compared to FY 2024. Operating income came in at $-746M.

In Q3 2025, Avidity Biosciences, Inc. reported revenue of $12M and earnings per share (EPS) of $-1.27. Net income for the quarter was $-174M. Revenue grew 434.0% year-over-year compared to Q3 2024. Operating income came in at $-189M.

In Q2 2025, Avidity Biosciences, Inc. reported revenue of $4M and earnings per share (EPS) of $-1.21. Net income for the quarter was $-157M. Revenue grew 88.1% year-over-year compared to Q2 2024. Operating income came in at $-171M.

Over the past 8 quarters, Avidity Biosciences, Inc. has demonstrated a growth trajectory, with revenue expanding from $2M to $20M. Investors analyzing RNA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RNA Dividend Yield and Income Analysis

Avidity Biosciences, Inc. (RNA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RNA Momentum and Technical Analysis Profile

Avidity Biosciences, Inc. (RNA) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

RNA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Avidity Biosciences, Inc. (RNA) ranks #797 out of 838 stocks based on the Blank Capital composite score. This places RNA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RNA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RNA vs S&P 500 (SPY) comparison to assess how Avidity Biosciences, Inc. stacks up against the broader market across all factor dimensions.

RNA Next Earnings Date

No upcoming earnings date has been announced for Avidity Biosciences, Inc. (RNA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RNA? — Investment Thesis Summary

The quantitative profile for Avidity Biosciences, Inc. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. High volatility (stability score 22/100) increases portfolio risk.

In summary, Avidity Biosciences, Inc. (RNA) earns a Avoid rating with a composite score of 28.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RNA stock.

Related Resources for RNA Investors

Explore more research and tools: RNA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RNA head-to-head with peers: RNA vs AZN, RNA vs SLGL, RNA vs VMD.